Suboptimal Statin Use in Diabetes Mellitus: Persistent Gaps Between Guidelines and Practice

Dear Editor,

Statin therapy is a cornerstone for cardiovascular risk reduction in patients with diabetes mellitus (DM), yet substantial gaps persist between guideline recommendations and real-world practice. The 2018 American Heart Association/American College of Cardiology (AHA/ACC) cholesterol guidelines recommend at least moderate-intensity statin therapy for all adults aged 40–75 years with DM, and high-intensity statins for those with multiple risk factors or established atherosclerotic cardiovascular disease (ASCVD).¹ Despite these clear recommendations, numerous studies have demonstrated that a significant proportion of eligible patients with DM are either not prescribed statins at all or receive suboptimal-intensity therapy, even in high-risk populations.²

Analyses of large registries and databases have found that up to one-third of statin-eligible diabetic patients are not treated. In contrast, many others receive low-intensity regimens that are unlikely to confer adequate ASCVD risk reduction.^3,4 Barriers to appropriate prescribing include concerns about adverse effects, therapeutic inertia, fragmented care, and inadequate risk stratification. Clinicians frequently miss opportunities to initiate or optimize statin therapy in hospitalized patients, particularly when admissions are for non-cardiovascular indications.

Failure to prescribe appropriate statin therapy in diabetics represents a missed opportunity to prevent myocardial infarction, stroke, and cardiovascular mortality. Randomized trials and meta-analyses have consistently shown that statins substantially reduce major vascular events in patients with DM, regardless of baseline low-density lipoprotein cholesterol levels.⁵ Interventions such as clinician education, electronic health record prompts aligned with AHA/ACC guidelines, pharmacist-led lipid management, and deliberate medication optimization at hospital discharge have been shown to improve statin uptake and intensity.^3,4 Improving adherence to evidence-based statin prescribing in patients with DM is an achievable and impactful strategy to reduce cardiovascular risk and enhance the quality of care.